Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
NCT00087815
Unknown
RATIONALE: Hyperbaric oxygen may increase blood flow and decrease swelling in areas of the brain damaged by radiation therapy. Giving hyperbaric oxygen therapy together with dexamethasone may be an effective treatment for radiation necrosis of the brain. PURPOSE: This randomized clinical trial is studying how well hyperbaric oxygen therapy works in treating patients with radiation necrosis of the brain.
Gender:
ALL
Ages:
All
Trial Updated:
12/17/2013
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Radiation Toxicity
Register for Updates
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00742404
Unknown
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving bortezomib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how wel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2013
Locations: Arizona Clinical Research Center, Incorporated, Tucson, Arizona +11 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
NCT00617591
Completed
The purpose of the research study is to determine the response rates when Revlimid® is combined with Doxil® and Dexamethasone (Dd-R) in newly diagnosed Multiple Myeloma. The study will also evaluate the side effects caused by the combination of these three drugs. This therapy is investigational in the treatment of Multiple Myeloma. Revlimid® is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2013
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
NCT01250717
Completed
The purpose of this research study is to determine if the combination of chemotherapy and hormone therapy is safe and helpful for patients who plan to have their high-risk prostate cancer surgically removed. Some physicians believe that patients with high risk cancer that is located in one area, may have an early but small spread of the cancer outside of the prostate, and perhaps even to distant organs. Therefore, better treatments for the entire body are needed to improve the ability of surgery... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/16/2013
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
NCT00750815
Completed
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL®, PLD), and Dexamethasone (VDD). The purpose of this study is to determine if the addition of another type of chemotherapy agent, Cyclophosphamide, to the regimen VDD (CVDD) is well tolerated and improves response rates in myeloma. We will also find the highest safe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate
NCT00156299
Terminated
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in cancer cells. It may also help doctors understand how cancer cells respond to treatment with choline magnesium trisalicylate. PURPOSE: This pilot clinical trial is studying gene expression in cancer cells during chemotherapy and the safety of choline magnesium trisalicylate in treating patients with newly diagnosed acute myeloid leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2013
Locations: Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
NCT00462787
Completed
RATIONALE: Drugs used in chemotherapy, such as clofarabine, topotecan, vinorelbine, thiotepa, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of clofarabine when given together with topotecan, vinorelbine, thiotepa, and dexamethasone in treating young pa... Read More
Gender:
ALL
Ages:
28 years and below
Trial Updated:
11/13/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Leukemia
Register for Updates
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
NCT01474915
Completed
This study is being done to determine the efficacies of two preventative drug combinations for postoperative nausea and vomiting in patients undergoing neurosurgery. The aim of this study is to compare the efficacy of using aprepitant instead of ondansetron in combination with dexamethasone and promethazine for post-operative nausea and vomiting prophylaxis. By completing this comparison study investigators will determine the most efficacious drug combination which will allow us to enhance the o... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/08/2013
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Postoperative Nausea and Vomiting (PONV), Nausea
Register for Updates
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
NCT01640340
Completed
Palonosetron is different from ondansetron because it stays in the body longer and may prevent nausea and vomiting for a longer period of time than ondansetron. It is standard practice to use dexamethasone and aprepitant with either ondansetron or palonosetron to prevent nausea and vomiting caused by highly emetogenic chemotherapy. Although these combinations are commonly used, they have never been compared to each other. The purpose of this study is to record the amount of nausea and vomiting,... Read More
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
10/13/2013
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Malignant Neoplasm
Register for Updates
Duration of Leg Nerve Blocks With Dexamethasone Added to Local Anesthetic
NCT01511211
Withdrawn
This is a Randomized Double blinded controlled trial on the effect of adding dexamethasone to Ropivacaine on the duration of pain relief for ultrasound guided femoral, obturator and popliteal block after total knee replacement surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2013
Locations: University of New Mexico Hospital, Albuquerque, New Mexico
Conditions: Pain, Total Knee Arthroplasty
Register for Updates
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00006002
Completed
RATIONALE: SU5416 may stop the growth of prostate cancer by stopping blood flow to the tumor. Dexamethasone may be effective in slowing the growth of prostate cancer cells. It is not yet known whether SU5416 or dexamethasone is more effective in treating progressive prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of SU5416 with that of dexamethasone in treating patients who have progressive prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/04/2013
Locations: Cancer Center and Beckman Research Institute, City of Hope, Duarte, California +17 locations
Conditions: Prostate Cancer
Register for Updates
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease
NCT00152620
Terminated
The aim of this therapeutic trial is to compare the response of subjects with active IBD to daily intravenous dexamethasone versus the response to daily intravenous methylprednisolone.
Gender:
ALL
Ages:
Between 6 years and 19 years
Trial Updated:
09/04/2013
Locations: University of Chicago Comer Children's Hospital, Chicago, Illinois
Conditions: Inflammatory Bowel Disease (IBD)
Register for Updates